No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy

No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy

BackgroundPatients with stage IV alveolar rhabdomyosarcoma (RMA) have a 5-year-survival rate not exceeding 30%. Here, we assess the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for these patients in comparison to standard-of-care regimens. We also compare the use of HLA-mis...

Full description

Bibliographic Details
Main Authors: Sebastian Johannes Schober, Erika Hallmen, Florian Reßle, Hendrik Gassmann, Carolin Prexler, Angela Wawer, Irene von Luettichau, Ruth Ladenstein, Bernarda Kazanowska, Gustaf Ljungman, Felix Niggli, Olli Lohi, Julia Hauer, Bernd Gruhn, Thomas Klingebiel, Peter Bader, Stefan Burdach, Peter Lang, Monika Sparber-Sauer, Ewa Koscielniak, Uwe Thiel
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Oncology
Subjects:
allogeneic stem cell transplantation
haploidentical
high-risk rhabdomyosarcoma
alveolar rhabdomyosarcoma (RMA) stage IV
matched-pair analysis
graft-versus-host disease
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.878367/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.878367/full

Similar Items